A Phase 3 interventional study of AFLIBERCEPT and Irinotecan in Colorectal Cancer Metastatic, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 5th largest by enrollment, is one of 7 that started in 2012, is one of 4 in phase 3, and was the 5th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
24 studies in Colorectal Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 24 studies in Colorectal Neoplasms by Sanofi, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2012, is one of 10 in phase 3, and was the 17th registered.
Sanofi’s Colorectal Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 24 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELOUR trial [EFC10262, NCT00561470]) according to side effects prevention and management guidelines.
Secondary Objective:
To document the Health-Related Quality of Life (HRQL) of aflibercept in this participant population.
Each participant was treated until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever come first). Participants were followed-up during treatment and for at least 30 days after its last study treatment (either Aflibercept or FOLFIRI) administration, up to a maximum of 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Related to Methodology
Related to Aflibercept:
Related to FOLFIRI
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
Drug: AFLIBERCEPT · Drug: Irinotecan · Drug: Fluorouracil · Drug: Leucovorin
Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Also known as: AVE0005
Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Percentage of Participants With Adverse Events (AEs)
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Time frame: Baseline upto 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure:723 days)
Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
Change From Baseline in HRQL EQ-5D-3L VAS Score
EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle; and at end of treatment (30 days after last study treatment) (maximum exposure: 99 weeks)
The study was conducted at 38 sites in France. A total of 182 participants were screened between 08 August 2012 and 30 June 2014, out of which 175 participants were enrolled and treated.
| Milestone | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Started | 175 |
| Completed | 122 |
| Not completed | 53 |
| Withdrew: Participant's decision | 15 |
| Withdrew: Other than specified above | 38 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period. On-treatment period was defined as the time from the first dose of treatment to 30 days after the last dose of treatment (either Aflibercept or FOLFIRI). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
| Percentage of participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Any TEAE | 100.00 |
| Any serious TEAE | 40.6 |
| Any serious related TEAE | 21.1 |
| Any TEAE leading to death | 9.1 |
| Any TEAE (permanent treatment discontinuation) | 23.4 |
| Any TEAE (premature treatment discontinuation) | 16.0 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline (n=148) | 69.54 ± 18.97 |
| At Cycle 3 (n=130) | -7.56 ± 19.78 |
| At Cycle 5 (n=99) | -10.86 ± 19.76 |
| At Cycle 7 (n=72) | -8.22 ± 20.00 |
| At Cycle 9 (n=51) | -9.31 ± 19.34 |
| At Cycle 11 (n=45) | -14.81 ± 21.24 |
| At Cycle 13 (n=25) | -12.67 ± 24.31 |
| At Cycle 15 (n=24) | -12.50 ± 18.22 |
| At Cycle 17 (n=14) | -14.29 ± 15.82 |
| At Cycle 19 (n=12) | -15.28 ± 11.70 |
| At Cycle 21 (n=10) | -15.83 ± 19.82 |
| At Cycle 23 (n=6) | -9.72 ± 20.01 |
| At Cycle 25 (n=4) | -8.33 ± 6.80 |
| At Cycle 27 (n=4) | -12.50 ± 15.96 |
| At Cycle 29 (n=2) | -8.33 ± 11.79 |
| At Cycle 31 (n=2) | -16.67 ± 0.00 |
| At Cycle 33 (n=1) | 0.00 ± NA |
| At Cycle 35 (n=1) | 0.00 ± NA |
| At Cycle 37 (n=2) | -8.33 ± 11.79 |
| At Cycle 39 (n=2) | -8.33 ± 11.79 |
| At Cycle 41 (n=2) | -8.33 ± 11.79 |
| At Cycle 43 (n=2) | -12.50 ± 5.89 |
| At Cycle 45 (n=2) | -4.17 ± 17.68 |
| At Cycle 47 (n=1) | 0.00 ± NA |
| At end of study treatment (n=73) | -11.19 ± 24.38 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline (n=148) | 0.78 ± 0.21 |
| At Cycle 3 (n=127) | -0.04 ± 0.23 |
| At Cycle 5 (n=96) | -0.08 ± 0.25 |
| At Cycle 7 (n=72) | -0.05 ± 0.20 |
| At Cycle 9 (n=49) | -0.09 ± 0.23 |
| At Cycle 11 (n=43) | -0.06 ± 0.20 |
| At Cycle 13 (n=24) | -0.09 ± 0.14 |
| At Cycle 15 (n=25) | -0.10 ± 0.16 |
| At Cycle 17 (n=14) | -0.03 ± 0.10 |
| At Cycle 19 (n=12) | -0.10 ± 0.12 |
| At Cycle 21 (n=10) | -0.03 ± 0.18 |
| At Cycle 23 (n=6) | -0.08 ± 0.15 |
| At Cycle 25 (n=3) | 0.04 ± 0.22 |
| At Cycle 27 (n=3) | -0.09 ± 0.20 |
| At Cycle 29 (n=2) | -0.18 ± 0.04 |
| At Cycle 31 (n=1) | 0.00 ± NA |
| At Cycle 37 (n=1) | -0.15 ± NA |
| At Cycle 39 (n=1) | 0.00 ± NA |
| At Cycle 41 (n=1) | 0.00 ± NA |
| At Cycle 43 (n=1) | 0.00 ± NA |
| At Cycle 45 (n=1) | 0.00 ± NA |
| At end of study treatment (n=71) | -0.20 ± 0.31 |
EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state. Baseline corresponded to last evaluable assessment before treatment administration.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline (n=125) | 69.48 ± 19.10 |
| At cycle 3 (n=94) | -6.23 ± 17.82 |
| At cycle 5 (n=76) | -7.62 ± 17.23 |
| At cycle 7 (n=57) | -7.79 ± 14.14 |
| At cycle 9 (n=38) | -7.55 ± 16.12 |
| At cycle 11 (n=36) | -8.67 ± 16.09 |
| At cycle 13 (n=22) | -8.95 ± 17.56 |
| At cycle 15 (n=22) | -12.41 ± 19.57 |
| At cycle 17 (n=13) | -10.31 ± 17.44 |
| At cycle 19 (n=10) | -15.70 ± 18.19 |
| At cycle 21 (n=8) | -15.13 ± 19.87 |
| At cycle 23 (n=5) | -8.80 ± 10.71 |
| At cycle 25 (n=2) | -13.00 ± 4.24 |
| At cycle 27 (n=3) | -15.67 ± 9.81 |
| At cycle 29 (n=2) | -17.50 ± 3.54 |
| At cycle 31 (n=1) | -15.00 ± NA |
| At cycle 37 (n=1) | -15.00 ± NA |
| At cycle 39 (n=1) | -15.00 ± NA |
| At cycle 41 (n=1) | -15.00 ± NA |
| At cycle 43 (n=1) | -15.00 ± NA |
| At cycle 45 (n=1) | -15.00 ± NA |
| At end of study treatment (n=55) | -13.05 ± 20.82 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 723) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin) | — | 71/175 (40.6%) | 172/175 (98.3%) |
| Event | Aflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin) |
|---|---|
| DISEASE PROGRESSIONGeneral disorders | 9/175 |
| DIARRHOEAGastrointestinal disorders | 8/175 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 8/175 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 4/175 |
| ABDOMINAL PAINGastrointestinal disorders | 3/175 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 3/175 |
| PYREXIAGeneral disorders | 3/175 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 2/175 |
| NAUSEAGastrointestinal disorders | 2/175 |
| SUBILEUSGastrointestinal disorders | 2/175 |
| Event | Aflibercept + FOLFIRI(Irinotecan, 5-Fluorouracil & Leucovorin) |
|---|---|
| DIARRHOEAGastrointestinal disorders | 121/175 |
| ASTHENIAGeneral disorders | 98/175 |
| NAUSEAGastrointestinal disorders | 86/175 |
| STOMATITISGastrointestinal disorders | 83/175 |
| HYPERTENSIONVascular disorders | 74/175 |
| WEIGHT DECREASEDInvestigations | 68/175 |
| DECREASED APPETITEMetabolism and nutrition disorders | 59/175 |
| VOMITINGGastrointestinal disorders | 47/175 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 43/175 |
| NEUTROPENIABlood and lymphatic system disorders | 39/175 |
| Age, Continuous(years) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Mean | 64.5 ± 11.0 |
| Sex: Female, Male(Participants) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Female | 77 |
| Male | 98 |
The record gives a start of Aug 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aflibercept · Irinotecan